[SCHEDULE 13G/A] Spero Therapeutics, Inc. SEC Filing
Anson-managed entities reported beneficial ownership of 1,615,469 shares of Spero Therapeutics common stock, representing 2.9% of the 55,910,641 shares outstanding. The holdings are disclosed on a Schedule 13G/A dated for the event 06/30/2025 and signed on 08/14/2025 by representatives of Anson Funds Management LP, Anson Management GP LLC, Anson Advisors Inc., Tony Moore, Amin Nathoo and Moez Kassam.
The filing states the shares are held by the Fund and that the position is held in the ordinary course of business and not to influence control of the issuer. Voting and dispositive power over the 1,615,469 shares is shown as shared (no sole power reported). The filing cites the issuer's outstanding share count from the issuer's May 13, 2025 quarterly report.
- None.
- None.
Insights
TL;DR: Anson group disclosed a passive 2.9% stake in SPRO, a non-controlling position that is unlikely to force near-term corporate changes.
The Schedule 13G/A reports 1,615,469 shares (2.9% of 55,910,641 shares). The filing classifies the position as held in the ordinary course of business and not intended to influence control, consistent with passive investor reporting thresholds. Shared voting and dispositive power is indicated across the Anson entities. For investors, this is a transparent ownership disclosure rather than an activist move; it signals interest but not control.
TL;DR: The disclosure documents beneficial ownership and shared authority but shows no group formation or control intent, so governance impact appears limited.
The filing lists multiple affiliated filers and confirms shared voting/dispositive power over 1,615,469 shares (2.9%). Item 10 certification states the stake was not acquired to change control. No members of a group, no greater-than-5% ownership, and no solicitation or group formation are reported. From a governance perspective, this is routine transparency with no immediate governance implications disclosed.